**Product Name:** ATB-346  
**Cat. No.:** HY-15028  
**CAS No.:** 1226895-20-0  
**Molecular Formula:** C_{21}H_{19}NO_S  
**Molecular Weight:** 365.45  
**Target:** COX  
**Pathway:** Immunology/Inflammation  
**Solubility:** DMSO: ≥ 51.6 mg/mL

**BIOLOGICAL ACTIVITY:**

ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.

**IC50 value:**

**Target:** COX-2  
ATB-346 suppressed gastric prostaglandin E(2) synthesis as effectively as naproxen, but produced negligible damage in the stomach and intestine. Unlike naproxen and celecoxib, ATB-346 accelerated healing of pre-existing gastric ulcers. In a mouse airpouch model, ATB-346 suppressed cyclooxygenase-2 activity and inhibited leukocyte infiltration more effectively than naproxen. ATB-346 was as effective as naproxen in adjuvant-induced arthritis in rats, with a more rapid onset of activity. Unlike naproxen, ATB-346 did not elevate blood pressure in hypertensive rats [1]. Treatment with ATB-346 exhibited a significantly more rapid and sustained recovery of motor function, achieving greater than double the increase in locomotion score of the naproxen group by the 10th day of treatment. ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI [2].

**References:**